Treatment of severe asthma

Home » FOI request log » Treatment of severe asthma

FOI REFERENCE: 24265 FOI DATE: 30^th July 2024

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between the start of April 2024 and end of June 2024?

Name of medicine		Number patients treated
1.1 Benralizumab (Fasenra)		27
1.2 Dupilumab (Dupixent)		31
1.3 Mepolizumab (Nucala)		18
1.4 Omalizumab (Xolair)		16
1.5 Reslizumab (Cinqaero)		0
1.6 Tezepelumab (Tezspire)		19

Q2. How many patients were treated for severe asthma, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other
2.1 Benralizumab (Fasenra)	27	*N/A*	*N/A*	*N/A*
2.2 Dupilumab (Dupixent)	*	0	27
2.3 Mepolizumab (Nucala)	18	0	*N/A*
2.4 Omalizumab (Xolair)	14	0	*N/A*	*
2.5 Reslizumab (Cinqaero)	0	*N/A*	*N/A*	*N/A*
2.6 Tezepelumab (Tezspire)	19	*N/A*	*N/A*	*N/A*

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018

Q3. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)	27
3.2 Dupilumab (Dupixent)	*	27
3.3 Mepolizumab (Nucala)	18
3.4 Omalizumab (Xolair)	14	*
3.5 Reslizumab (Cinqaero)	0	0
3.6 Tezepelumab (Tezspire)	19

Print this page

Email this page

Treatment of severe asthma

In this section